PRMT5 and glioblastoma: Interestingly, patient GSC samples identified as being mostly proneural, based on RNA sequencing (RNA-seq) data and TCGA criteria, were enriched within the more sensitive GSC lines (Fig. 2b), suggesting that GBM patients with more proneural subtype tumors may be more sensitive to PRMT5 inhibitors.